Gene- and Viral-Based Therapies for Brain Tumors

Neurotherapeutics

Volumn 6, Issue 3, 2009, Pages 547-557

  Asadi Moghaddam, Kaveh ^a   Chiocca, E Antonio ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

clinical trial; gene therapy; Glioma; oncolytic virus

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA INTERFERON; CEREPRO; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; G 207; GAMMA INTERFERON; GANCICLOVIR; HERPES SIMPLEX VIRUS 1 THYMIDINE KINASE; INTERLEUKIN 2; ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC NEWCASTLE DISEASE VIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; ONYX 015; PROTEIN P53; REPLICATION COMPETENT RETROVIRAL VECTOR; RETROVIRUS VECTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VASCULOTROPIN; VIRUS ENZYME; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; ANTISENSE THERAPY; ARTICLE; BRAIN TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER GENE THERAPY; CANDIDIASIS; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; GENE DELIVERY SYSTEM; GENE TARGETING; GENE TRANSFER; GLIOBLASTOMA; GLIOMA; HUMAN; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SUICIDE GENE THERAPY; SURVIVAL TIME;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEUROIMMUNOMODULATION; TRANSDUCTION, GENETIC;

EID: 67649277701     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.04.007     Document Type: Article

References (102)

1. Anwer K. Formulations for DNA delivery via electroporation in vivo. Methods Mol Biol 423 (2008) 77-89
2. Rice J., Ottensmeier C., and Stevenson F. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8 (2008) 108-120
3. Lechardeur D., and Lukacs G. Nucleocytoplasmic transport of plasmid DNA: a perilous journey from the cytoplasm to the nucleus. Hum Gene Ther 17 (2006) 882-889
4. Vaughan E., DeGiulio J., and Dean D. Intracellular trafficking of plasmids for gene therapy: mechanisms of cytoplasmic movement and nuclear import. Curr Gene Ther 6 (2006) 671-681
5. Bergen J., Park I., Horner P., and Pun S. Nonviral approaches for neuronal delivery of nucleic acids. Pharm Res 25 (2008) 983-998
6. Niidome T., and Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 9 (2002) 1647-1652
7. Faulds D., and Heel R. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39 (1990) 597-638
8. Chen S., Shine H., Goodman J., Grossman R., and Woo S. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 91 (1994) 3054-3057
9. Culver K., Ram Z., Wallbridge S., et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256 (1992) 1550-1552
10. Ezzeddine Z., Martuza R., Platika D., et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 3 (1991) 608-614
11. Ram Z., Culver K., Walbridge S., Blaese R., and Oldfield E. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53 (1993) 83-88
12. Freeman S., Abboud C., Whartenby K., et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53 (1993) 5274-5283
13. Fick J., Barker F., Dazin P., et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci U S A 92 (1995) 11071-11075
14. Ram Z., Walbridge S., Shawker T., et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 81 (1994) 256-260
15. Barba D., Hardin J., Sadelain M., and Gage F. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 91 (1994) 4348-4352
16. Kim J., Kim S., Kolozsvary A., et al. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 33 (1995) 861-868
17. Nestler U., Wakimoto H., Siller-Lopez F., et al. The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol 67 (2004) 177-188
18. Aghi M., Kramm C., Chou T., Breakefield X., and Chiocca E. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 90 (1998) 370-380
19. Miller C., Williams C., Buchsbaum D., and Gillespie G. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 62 (2002) 773-780
20. Wei M., Tamiya T., Chase M., et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5 (1994) 969-978
21. Clarke L., and Waxman D. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49 (1989) 2344-2350
22. Manome Y., Wen P., Chen L., et al. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther 3 (1996) 513-520
23. Wei M., Tamiya T., Rhee R., Breakefield X., and Chiocca E. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1 (1995) 1171-1177
24. Sathornsumetee S., Reardon D., Desjardins A., et al. Molecularly targeted therapy for malignant glioma. Cancer 110 (2007) 13-24
25. Vousden K., and Lane D. p53 in health and disease. Nat Rev Mol Cell Biol 8 (2007) 275-283
26. Louis D., Holland E., and Cairncross J. Glioma classification: a molecular reappraisal. Am J Pathol 159 (2001) 779-786
27. Li H., Alonso-Vanegas M., Colicos M., et al. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 5 (1999) 637-642
28. Roth J. Adenovirus p53 gene therapy. Expert Opin Biol Ther 6 (2006) 55-61
29. von Deimling A., Louis D., and Wiestler O. Molecular pathways in the formation of gliomas. Glia 15 (1995) 328-338
30. Louis D. Molecular pathology of malignant gliomas. Annu Rev Pathol 1 (2006) 97-117
31. Inoue R., Moghaddam K., Ranasinghe M., et al. Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther 11 (2004) 1195-1204
32. Huang P., Cavenee W., Furnari F., and White F. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle 6 (2007) 2750-2754
33. Lang F., Bruner J., Fuller G., et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21 (2003) 2508-2518
34. Gansbacher B., Zier K., Daniels B., et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172 (1990) 1217-1224
35. Sobol R., Fakhrai H., Shawler D., et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2 (1995) 164-167
36. Yu J., Wei M., Chiocca E., Martuza R., and Tepper R. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 53 (1993) 3125-3128
37. Parker J., Gillespie G., Love C., et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 97 (2000) 2208-2213
38. Qin X., Tao N., Dergay A., et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci U S A 95 (1998) 14411-14416
39. Gansbacher B., Bannerji R., Daniels B., et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50 (1990) 7820-7825
40. Herrlinger U., Kramm C., Johnston K., et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4 (1997) 345-352
41. Fearon E., Pardoll D., Itaya T., et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60 (1990) 397-403
42. Tjuvajev J., Gansbacher B., Desai R., et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 55 (1995) 1902-1910
43. Chiocca E., Smith K., McKinney B., et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16 (2008) 618-626
44. Im S., Gomez-Manzano C., Fueyo J., et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59 (1999) 895-900
45. Millauer B., Shawver L., Plate K., Risau W., and Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 (1994) 576-579
46. Van Meir E., Polverini P., Chazin V., et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 8 (1994) 171-176
47. Kim S., Kim S., and Robbins P. Retroviral vectors. Adv Virus Res 55 (2000) 545-563
48. Young L., Searle P., Onion D., and Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 208 (2006) 299-318
49. Tai C., and Kasahara N. Replication-competent retrovirus vectors for cancer gene therapy. Front Biosci 13 (2008) 3083-3095
50. Wang W., Tai C.K., Kershaw A.D., et al. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 20 (2006) E25
51. Rainov N., and Kramm C. Recombinant retrovirus vectors for treatment of malignant brain tumors. Int Rev Neurobiol 55 (2003) 185-203
52. Ram Z., Culver K., Walbridge S., et al. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 79 (1993) 400-407
53. Long Z., Li L., Grooms T., et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 9 (1998) 1165-1172
54. Uren A., Kool J., Berns A., and van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. Oncogene 24 (2005) 7656-7672
55. Fehse B., and Roeder I. Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther 15 (2008) 143-153
56. Roth J., Nguyen D., Lawrence D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2 (1996) 985-991
57. Tait D., Obermiller P., Redlin-Frazier S., et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 3 (1997) 1959-1968
58. Freimuth P., Philipson L., and Carson S. The coxsackievirus and adenovirus receptor. Curr Top Microbiol Immunol 323 (2008) 67-87
59. Waehler R., Russell S., and Curiel D. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8 (2007) 573-587
60. Douglas J. Adenoviral vectors for gene therapy. Mol Biotechnol 36 (2007) 71-80
61. Sandmair A., Vapalahti M., and Yla-Herttuala S. Adenovirus-mediated herpes simplex thymidine kinase gene therapy for brain tumors. Adv Exp Med Biol 465 (2000) 163-170
62. Vecil G., and Lang F. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65 (2003) 237-246
63. Chiocca E.A., Smith K.M., McKinney B., et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16 (2008) 618-626
64. Verma I., and Somia N. Gene therapy - promises, problems and prospects. Nature 389 (1997) 239-242
65. Hartman Z., Appledorn D., and Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132 (2008) 1-14
66. Chiocca E. The host response to cancer virotherapy. Curr Opin Mol Ther 10 (2008) 38-45
67. Bischoff J., Kirn D., Williams A., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
68. Heise C., Sampson-Johannes A., Williams A., et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3 (1997) 639-645
69. Hollstein M., Rice K., Greenblatt M., et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22 (1994) 3551-3555
70. Rutka J., Akiyama Y., Lee S., et al. Alterations of the p53 and pRB pathways in human astrocytoma. Brain Tumor Pathol 17 (2000) 65-70
71. Sherr C. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 (2001) 731-737
72. O'Shea C., Johnson L., Bagus B., et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6 (2004) 611-623
73. Heise C., Hermiston T., Johnson L., et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6 (2000) 1134-1139
74. Martuza R., Malick A., Markert J., Ruffner K., and Coen D. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252 (1991) 854-856
75. Aghi M., Visted T., Depinho R., and Chiocca E. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 27 (2008) 4249-4254
76. Cassady K., Gross M., and Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 72 (1998) 7005-7011
77. Farassati F., Yang A., and Lee P. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3 (2001) 745-750
78. Smith K., Mezhir J., Bickenbach K., et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 80 (2006) 1110-1120
79. Veerapong J., Bickenbach K., Shao M., et al. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 67 (2007) 8301-8306
80. Balachandran S., and Barber G. PKR in innate immunity, cancer, and viral oncolysis. Methods Mol Biol 383 (2007) 277-301
81. Mineta T., Rabkin S., Yazaki T., Hunter W., and Martuza R. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1 (1995) 938-943
82. Aghi M.K., and Chiocca E.A. Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther 17 (2009) 8-9
83. Markert J., Medlock M., Rabkin S., et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7 (2000) 867-874
84. Markert J.M., Liechty P.G., Wang W., et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17 (2009) 199-207
85. Dorig R.E., Marcil A., Chopra A., and Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75 (1993) 295-305
86. Schneider U., von Messling V., Devaux P., and Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J Virol 76 (2002) 7460-7467
87. Allen C., Paraskevakou G., Liu C., et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 8 (2008) 213-220
88. Forsyth P., Roldan G., George D., et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16 (2008) 627-632
89. Freeman A., Zakay-Rones Z., Gomori J., et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13 (2006) 221-228
90. Ram Z., Culver K., Oshiro E., et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3 (1997) 1354-1361
91. Klatzmann D., Valery C., Bensimon G., et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9 (1998) 2595-2604
92. Shand N., Weber F., Mariani L., et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10 (1999) 2325-2335
93. Packer R., Raffel C., Villablanca J., et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 92 (2000) 249-254
94. Rainov N. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11 (2000) 2389-2401
95. Puumalainen A., Vapalahti M., Agrawal R., et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9 (1998) 1769-1774
96. Immonen A., Vapalahti M., Tyynela K., et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomized, controlled study. Mol Ther 10 (2004) 967-972
97. Rampling R., Cruickshank G., Papanastassiou V., et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7 (2000) 859-866
98. Harrow S., Papanastassiou V., Harland J., et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11 (2004) 1648-1658
99. Harland J., Papanastassiou V., and Brown S.M. HSV1716 persistence in primary human glioma cells in vitro. Gene Ther 9 (2002) 1194-1198
100. Herrlinger U., Woiciechowski C., Sena-Esteves M., et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 1 (2000) 347-357
101. Aboody K.S., Brown A., Rainov N.G., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97 (2000) 12846-12851
102. Ferguson S.D., Foster K., and Yamini B. Convection-enhanced delivery for treatment of brain tumors. Expert Rev Anticancer Ther 7 (2007) S79-S85